2025 ESMO Impact Survey
The Syneos Health ESMO 2025 Impact Survey captures insights from 102 global oncologists on the data, manufacturers and modalities shaping the future of cancer care. This year’s findings reveal a notable rise in clinical excitement, with antibody–drug conjugates (ADCs), TROP2 and LAG-3 targets and new checkpoint inhibitors leading the conversation — all pointing to another step forward in oncology innovation and the evolution of standard of care.
Key Findings
- Excitement Up Year-over-Year: 72% of oncologists reported high or complete satisfaction with ESMO 2025 data (vs. 65% in 2024).
- ADCs Lead the Way: Antibody–drug conjugates remain the most anticipated class, with HER2+ and triple-negative breast cancer data driving interest.
- Emerging Molecular Targets: TROP2, LAG-3, Claudin 18.2, HER3, and DLL3 identified as top targets expected to reshape treatment paradigms.
- Next-Generation Modalities: CAR-T, TIL and NK cell therapies rated as the most exciting cell-based innovations.
- Tumor Types Seeing Transformation: Breast and genitourinary cancers expected to experience the greatest shifts in treatment practice based on new ESMO data.
Why It Matters
ESMO 2025 reflects an oncology landscape accelerating toward precision and convergence — where new modalities, emerging players and global collaboration are expanding treatment frontiers faster than ever before.
Download the ESMO 2025 Impact Survey to see which data, targets and innovations are shaping oncology’s future.
Related Content
Looking for exclusive insight?
